Alexion

Overview

Alexion, AstraZeneca Rare Disease, is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US.

US/UNB-a/0460

Patient Assistance Programs

• OneSourceTM is a complimentary, personalized patient support program offered by Alexion and tailored to the specific needs of people living with aHUS (atypical Hemolytic Uremic Syndrome), PNH (Paroxysmal Nocturnal Hemoglobinuria), gMG (generalized Myasthenia Gravis), NMOSD (Neuromyelitis Optica Spectrum Disorder), HPP (Hypophosphatasia), LAL-D (Lysosomal Acid Lipase Deficiency), and NF1 (Neurofibromatosis Type 1). For more information, please call 1-888-765-4747 or visit https://alexiononesource.com/

• Visit https://pnhsource.com/ for PNH patient and caregiver resources
• Visit https://ahussource.com/ for aHUS patient and caregiver resources

For order inquires, customer operations, case management, medical information, product complaints, or to inquire about the REMS (Risk Evaluation and Mitigation Strategy) programs, please call 1-888-765-4747.